Clinical Trial Update: A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis [Phase 2]

View source ↗

Summary

Phase II trial completed evaluating Hydronidone capsules (F351) for liver fibrosis due to chronic Hepatitis B infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Liver Fibrosis

Drugs mentioned

• Hydronidone capsules (F351)

Snippet

Sponsor: Shanghai Genomics, Inc. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED